Amesite Inc. shares surged sharply in after-hours trading Monday after the Detroit-based company announced its largest enterprise deployment yet for its AI-native NurseMagic documentation platform.
The stock climbed 90.82 percent to $1.50 following the news that a new customer will roll out the tool across a 2,700-patient census. The move marks a substantial increase in scale for Amesite and underscores its focus on the enterprise healthcare market.
Company officials described the deployment as a key step in shifting NurseMagic from an assistive tool to core clinical infrastructure. CEO Dr. Ann Marie Sastry said, “This achievement reflects the successful transition from an assistive tool to core clinical infrastructure in the $1.5T+ non-acute/post-acute market.”
The announcement came alongside the release of third-quarter financial results. Amesite reported revenue of $83,330, representing a roughly 171 percent increase from the same period a year earlier. The company posted a loss per share of $0.15.
Amesite develops AI-powered applications aimed at the healthcare and education sectors. Its market capitalization stands at $4.16 million, according to the latest figures. The stock has ranged between a 52-week high of $4.78 and a low of $0.77 over the past year.
During regular trading on Monday, AMST closed at $0.79, down 4.58 percent. The shares have fallen 74.06 percent over the trailing 12 months and currently trade near their 52-week low.
Technical indicators show the stock with a Relative Strength Index of 29.32. Benzinga’s Edge Stock Rankings indicate a negative price trend across all time frames examined.
The new customer deployment targets the non-acute and post-acute care segments, areas where documentation time reduction can have a direct impact on operations. NurseMagic is designed specifically to streamline patient documentation processes for clinical staff.
Market observers noted that the after-hours move came on elevated volume as traders reacted to both the contract win and the year-over-year revenue growth. The company has positioned itself as a provider of AI solutions that integrate into existing clinical workflows.
With a relatively small market capitalization, AMST remains sensitive to news of new enterprise agreements. The latest customer represents the largest single deployment announced to date by the company.
Officials have not disclosed the identity of the new customer or the financial terms of the agreement. Further details on the rollout timeline are expected in future updates.
Investors will likely watch for additional contract announcements and updates on revenue trends in the coming quarters as Amesite continues to expand its presence in the healthcare technology space.